{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:01:55Z","timestamp":1789779715115,"version":"4.0.1"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"Importance<\/jats:title>Although clinical practice guidelines exist for the treatment of infantile hemangiomas (IHs), recommendations are heterogeneous, and wide practice variations in IH management have been reported.<\/jats:p><\/jats:sec>Objective<\/jats:title>To analyze the degree of agreement in treatment choices for IH among pediatric dermatologists in North America and Europe and assess whether there are differences across IH risk categories.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional interrater and intrarater agreement study was conducted through a survey based on the Spanish Academy of Dermatology and Venereology IH prospective cohort. The survey used 50 vignettes of IH cases that were randomly selected from the cohort. It was administered twice in 2023, 1 month apart, to allow for interrater and intrarater agreement assessments. Data were analyzed in January 2024. The study involved pediatric dermatologists from North America (via the Pediatric Dermatology Research Alliance) and Europe (via the European Society of Pediatric Dermatologists).<\/jats:p><\/jats:sec>Exposures<\/jats:title>Participants were asked to choose 1 of 3 treatment options (propranolol, topical timolol, or observation) for each vignette.<\/jats:p><\/jats:sec>Main Outcome and Measure<\/jats:title>The primary outcome was the interrater agreement in treatment choices for IH cases, measured using \u03ba statistics (Gwet AC1 coefficient).<\/jats:p><\/jats:sec>Results<\/jats:title>The global interobserver agreement among 90 pediatric dermatologists was fair (AC1, 0.38; 95% CI, 0.29-0.46). In North America (45 pediatric dermatologists), agreement was moderate (AC1, 0.41; 95% CI, 0.33-0.49), while in Europe (45 pediatric dermatologists) it was fair (AC1, 0.37; 95% CI, 0.28-0.46). The degree of agreement varied depending on the risk category of IH, with excellent agreement in high-risk IH and only moderate agreement in intermediate-risk and low-risk IHs. Propranolol was predominantly chosen for high-risk IH, while observation was most frequent for low-risk IH (55.9%). The second survey had 61 respondents, with no significant intrarater differences.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The results of this survey study suggest that there is an important variability in the treatment of intermediate-risk and low-risk IH. The study findings support the need for more evidence regarding the role of topical timolol in IH treatment, which may help harmonize treatment approaches and improve consistency in IH management globally.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.5125","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T16:00:53Z","timestamp":1734537653000},"page":"203","source":"Crossref","is-referenced-by-count":4,"title":["Interobserver and Intraobserver Agreement on the Treatment of Infantile Hemangiomas"],"prefix":"10.1001","volume":"161","author":[{"given":"Mar\u00eda","family":"Colmenero-Sendra","sequence":"first","affiliation":[{"name":"Dermatology Department, Hospital Costa del Sol, Marbella, Spain"},{"name":"Programa de Doctorado en Medicina Cl\u00ednica y Salud P\u00fablica, Universidad de Granada, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"del Boz-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Regional Universitario de M\u00e1laga, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Grau-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Research Unit, Spanish Academy of Dermatology and Venereology, Madrid, Spain"},{"name":"Dermatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Descalzo-Gallego","sequence":"additional","affiliation":[{"name":"Research Unit, Spanish Academy of Dermatology and Venereology, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garc\u00eda-Doval","sequence":"additional","affiliation":[{"name":"Research Unit, Spanish Academy of Dermatology and Venereology, Madrid, Spain"},{"name":"Dermatology Department, Hospital do Meixoeiro, Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulalia","family":"Baselga Torres","sequence":"additional","affiliation":[{"name":"Dermatology Department. Hospital Sant Joan de Deu, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"dbr240022r1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma.","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"dbr240022r2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamapediatrics.2021.4565","article-title":"Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial.","volume":"176","author":"Pope","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"3","key":"dbr240022r3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000510029","article-title":"The efficacy and safety of topical \u00df-blockers in treating infantile hemangiomas: a meta-analysis including 11 randomized controlled trials.","volume":"237","author":"Wang","year":"2021","journal-title":"Dermatology"},{"issue":"1","key":"dbr240022r4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1573396316666200508100038","article-title":"Infantile hemangioma: an updated review.","volume":"17","author":"Leung","year":"2021","journal-title":"Curr Pediatr Rev"},{"issue":"7","key":"dbr240022r5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00431-015-2570-0","article-title":"Treatment of infantile haemangiomas: recommendations of a European expert group.","volume":"174","author":"Hoeger","year":"2015","journal-title":"Eur J Pediatr"},{"key":"dbr240022r6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.anpedi.2015.10.004","article-title":"Consenso Espa\u00f1ol sobre el hemangioma infantil.","volume":"85","author":"Baselga Torres","year":"2016","journal-title":"An Pediatr"},{"issue":"1","key":"dbr240022r7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1542\/peds.2018-3475","article-title":"Clinical practice guideline for the management of infantile hemangiomas.","volume":"143","author":"Krowchuk","year":"2019","journal-title":"Pediatrics"},{"issue":"3","key":"dbr240022r8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/bjd.16779","article-title":"Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines.","volume":"179","author":"Solman","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"dbr240022r9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jdin.2020.06.005","article-title":"International heterogeneity in admission criteria and monitoring for the initiation of propranolol in infantile hemangioma.","volume":"1","author":"Der Sarkissian","year":"2020","journal-title":"JAAD Int"},{"key":"dbr240022r10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.ad.2021.05.007","article-title":"Baseline description of the Spanish Academy of Dermatology infantile haemangioma nationwide prospective cohort: comparison of patients treated with propranolol in routine clinical practice with previous pivotal clinical trial data.","volume":"112","author":"Cuenca-Barrales","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"dbr240022r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2024.06.010","article-title":"Parental assessment of infantile haemangioma cosmetic outcomes: results of the Spanish haemangioma prospective cohort.","author":"Colmenero-Sendra","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"dbr240022r12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/pde.15015","article-title":"Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain.","volume":"39","author":"Colmenero","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"dbr240022r13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2288-13-61","article-title":"A comparison of Cohen\u2019s kappa and Gwet\u2019s AC1 when calculating inter-rater reliability coefficients: a study conducted with personality disorder samples.","volume":"13","author":"Wongpakaran","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"dbr240022r14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/pde.12435","article-title":"Outpatient use of oral propranolol and topical timolol for infantile hemangiomas: survey results and comparison with propranolol consensus statement guidelines.","volume":"32","author":"Kumar","year":"2015","journal-title":"Pediatr Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2827596\/jamadermatology_colmenerosendra_2024_br_240022_1742579725.64526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T15:06:46Z","timestamp":1743001606000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2827596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.5125","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}